Fig. 7 | Nature Communications

Fig. 7

From: Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease

Fig. 7

Cellular contributors to cfDNA in cancer. ac Predicted contributions of breast, colon, and lung DNA to the plasma methylome of four patients with colon cancer (CC), four patients with lung cancer (LC), three patients with breast cancer (BRC), and four healthy donors (H). All patients were at advanced stages of disease. d A mix-in experiment. The plasma of a patient with advanced colon cancer was mixed with three healthy plasma samples in varying proportions (detailed in Supplementary Data 1), and the fraction of colon-derived cfDNA was assessed using deconvolution of the methylome. e Identification of prostate-derived cfDNA in published plasma methylomes of patients with prostate cancer35 before and after treatment. Patients classified as abiraterone acetate (AA) treatment responsive (blue) show a dramatic drop in prostate-derived cfDNA, compared with the AA-resistant patients (red). f Deconvolution of cfDNA methylation predicts cfDNA origin for CUP cancer patients. Shown are the predicted cellular contributors for cfDNA samples from four patients diagnosed with a Cancer of Unknown Primary (CUP). Blood cell types and cells contributing <1% are not shown. For each patient, the location of metastases and the presumed tissue source of cancer according to clinical history are listed. Deconvolution results agreeing with clinical predictions are shown as orange bars. Error bars: SD, as estimated using Bootstrapping

Back to article page